POPULARITY
Categories
172 episodes with Ashish
147 episodes with Ashish
82 episodes with Ashish
101 episodes with Ashish
246 episodes with Ashish
71 episodes with Ashish
52 episodes with Ashish
13 episodes with Ashish
11 episodes with Ashish
12 episodes with Ashish
15 episodes with Ashish
40 episodes with Ashish
263 episodes with Ashish
6 episodes with Ashish
42 episodes with Ashish
23 episodes with Ashish
12 episodes with Ashish
12 episodes with Ashish
7 episodes with Ashish
11 episodes with Ashish
5 episodes with Ashish
7 episodes with Ashish
4 episodes with Ashish
15 episodes with Ashish
7 episodes with Ashish
12 episodes with Ashish
5 episodes with Ashish
7 episodes with Ashish
4 episodes with Ashish
5 episodes with Ashish
2 episodes with Ashish
3 episodes with Ashish
8 episodes with Ashish
6 episodes with Ashish
8 episodes with Ashish
4 episodes with Ashish
4 episodes with Ashish
3 episodes with Ashish
3 episodes with Ashish
4 episodes with Ashish
3 episodes with Ashish
2 episodes with Ashish
2 episodes with Ashish
4 episodes with Ashish
6 episodes with Ashish
In this episode, Ashish Vidyarthi invites you to look deeper — not at the world, but at yourself. In a compelling and heartfelt conversation on belief and courage, he challenges you to confront the one question that defines every life journey: Do you trust the person staring back at you?In “खुद पर भरोसा रखो,” Ashish strips away the noise of external expectations and asks us to feel the weight of our own potential. When fear whispers “you can't,” he shows how belief can whisper back, “watch me.” This isn't just motivation — it's a mirror held up to your own aspirations, reminding you that every great change starts with one simple truth: your belief in yourself is your greatest strength. Listen to this episode and let it awaken the courage you already carry within. Alshukran Bandhu,Alshukran Zindagi.Come be a part of My YouTube Family ️Subscribe To my YouTube Channels️ @AshishVidyarthiActorVlogs ️ @fiftypluszindagi ️ @FoodKhaanaWithAshishVidyarthi ️ @AshishVidyarthiPodcast ️ @KahaniyaanWithAshishVidyarthi Press the bell icon to be the first to get notified each time I upload a new video
Is AI security just "Cloud Security 2.0"? Toni De La Fuente, creator of the open-source tool Prowler, joins Ashish to explain why securing AI workloads requires a fundamentally different approach than traditional cloud infrastructure.We dive deep into the "Shared Responsibility Gap" emerging with managed AI services like AWS Bedrock and OpenAI. Toni spoke about the hidden dangers of default AI architectures, why you should never connect an MCP (Model Context Protocol) directly to a database.We discuss the new AI-driven SDLC, where tools like Claude Code can generate infrastructure but also create massive security blind spots if not monitored.Guest Socials - Toni's LinkedinPodcast Twitter - @CloudSecPod If you want to watch videos of this LIVE STREAMED episode and past episodes - Check out our other Cloud Security Social Channels:-Cloud Security Podcast- Youtube- Cloud Security Newsletter If you are interested in AI Security, you can check out our sister podcast - AI Security PodcastQuestions asked:(00:00) Introduction(02:50) Who is Toni De La Fuente? (Creator of Prowler)(03:50) AI Security vs. Cloud Security: What's the Difference? (07:20) The Shared Responsibility Gap in AI Services (Bedrock, OpenAI) (11:30) The "Fifth Party" Risk: Managed AI Access (13:40) AI Architecture Best Practices: Never Connect MCP to DB Directly (16:40) Prowler's AI Pillars: Generating Dashboards & Detections (22:30) The New SDLC: Securing Code from Claude Code & Lovable (25:30) The "Magic" Trap: Why AI Doesn't Know Your Security Context (28:30) Top 3 Priorities for Security Leaders (Infra, LLM, Shadow AI) (30:40) Future Predictions: Why Predicting 12 Months Out is Impossible
AI is having two seemingly contradictory effects on the markets, says Ashish Utarid, Assistant Vice-President, Investment Strategy, IG Wealth Management. AI's spending and projects are real, and the investment amounts are stratospheric. At the same time, AI is disrupting today's reality, and the market is already pricing in that disruption before it's even had a chance to affect companies' balance sheets. Ashish explains what this means for the markets and investors.
In this episode, Carl sits down with Ashish Gupta, founder of ScaleUp Exec, to discuss business turnarounds, leadership decisions, and culture resets. Ashish shares how he acquired a struggling company, realized innovation had stopped, and eventually rebuilt the team to change the company's trajectory. Key takeaways: Why the business must come first How to identify thinking leaders during interviews The role of systems before people and process When AI tools help — and when they fail How founders define success differently This episode offers practical insights for entrepreneurs and operators who want alignment between strategy and execution. Listen now and start measuring your success. Guest Assets: LinkedIn https://www.linkedin.com/in/ashish-gup/ Website https://scaleupexec.com/
What if the biggest thing holding you back isn't your idea… it's the way you've been trained to think?Ashish Bhatia is basically a therapist for entrepreneurs and in this episode of This Is Small Business, he breaks down why “just be confident” is the worst advice ever, and what actually works instead.As a professor of Entrepreneurship at NYU Stern, Ashish has helped hundreds of founders go from “I have an idea” to “I built this” and he's here to teach you how to rewire your brain for uncertainty, feedback, and real momentum. You'll learn why entrepreneurs aren't “natural risk-takers,” how to stop protecting your idea like it's fragile, and the simple steps to move faster (without spiraling). Plus: how to figure out what you really want so you stop building a life that looks good on paper but feels wrong in real life.If you've been stuck overthinking, waiting for the “right time,” or quietly questioning whether you're cut out for this… this one's for you.Watch the full conversation on YouTube: www.youtube.com/@ThisissmallbusinessIn this episode of This Is Small Business, you'll learn about:(01:11) — Mindset isn't enough… so what actually has to change?(06:41) — The 3 steps to go from “I have an idea” to “I built this”(08:44) — Why you're scared to share your idea (and how to do it anyway)(11:49) — Opportunity cost vs. “affordable loss” (A.K.A. How to stop talking yourself out of it)(14:20) — Why you need to self-reflect to build a successful business
Check out BeerBiceps SkillHouse's YouTube 1O1 Course - https://youtube.beerbicepsskillhouse.in/youtube-101Share your guest suggestions hereMail - connect@beerbiceps.comLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9For all BeerBiceps vlog content Watch Life Of BeerBiceps - https://www.youtube.com/@LifeOfBeerBicepsBeerBiceps SkillHouse को Social Media पर Follow करे :-YouTube : https://www.youtube.com/channel/UC2-Y36TqZ5MH6N1cWpmsBRQ Instagram : https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comLevel Supermind - Mind Performance App को Download करिए यहाँ से
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
Tucked away at Raffles Hotel is a new start-up with a hefty six figure annual fee for members. It aims to help its members live longer, healthier lives with preventive health checks and premium therapies on the market. Michelle Martin sits down with Ashish Chordia, Co-Founder and CEO of ELYX, to explore Singapore’s first concierge longevity service at Raffles Hotel. Instead of fragmented advice and annual check-ups, ELYX offers a coordinated “Circle of Experts” supported by an AI Healthspan Co-Pilot and research team. We unpack how data can dynamically shape health in this deep dive into the future of personalised health optimisation and executive longevity - hosted by Michelle Martin.See omnystudio.com/listener for privacy information.
In the world of Generative AI, natural language has become the new executable. Attackers no longer need complex code to breach your systems, sometimes, asking for a "poem" is enough to steal your passwords .In this episode, Eduardo Garcia (Global Head of Cloud Security Architecture at Check Point) joins Ashish to explain the paradigm shift in AI security. He shares his experience building AI-powered fraud detection systems and why traditional security controls fail against intent-based attacks like prompt injection and data poisoning .We dive deep into the reality of Shadow AI, where employees unknowingly train public models with sensitive corporate data , and the sophisticated world of Deepfakes, where attackers can bypass biometric security using AI-generated images unless you're tracking micro-movements of the eye .Guest Socials - Eduardo's LinkedinPodcast Twitter - @CloudSecPod If you want to watch videos of this LIVE STREAMED episode and past episodes - Check out our other Cloud Security Social Channels:-Cloud Security Podcast- Youtube- Cloud Security Newsletter If you are interested in AI Security, you can check out our sister podcast - AI Security Podcast(00:00) Introduction(01:55) Who is Eduardo Garcia? (Check Point)(03:00) Defining Security for GenAI: The Focus on Prompts (05:20) Why Natural Language is the New Executable (08:50) Multilingual Attacks: Bypassing Filters with Mandarin (12:00) Shift Left vs. Shift Right: The 70/30 Rule for AI Security (15:30) The "Poem Hack": Stealing Passwords with Creative Prompts (21:00) Shadow AI: The "HR Spreadsheet" Leak Scenario (25:40) Security vs. Compliance in a Blurring World (28:00) The Conflict: "My Budget Doesn't Include Security" (34:00) The 5 V's of AI Data: Volume, Veracity, Velocity (40:00) Deepfakes & Biometrics: Detecting Micro-Movements (43:40) Fun Questions: Soccer, Family, and Honduran Tacos
In this episode, Brad Hibbert (COO & Chief Strategy Officer at Brinqa) joins Ashish to explain why traditional risk-based vulnerability management (RBVM) is no longer enough in a cloud-first world .We explore the evolution from simple patch management to Exposure Management a holistic approach that sits above your security tools to connect infrastructure, code, and cloud risks to actual business impact . Brad breaks down the critical difference between a "Risk Owner" (the service owner) and a "Remediation Owner" (the team fixing the bug) and why this distinction solves the "who fixes this?" problem .This conversation covers practical steps to uplift your VM program, how AI is helping prioritize the noise , and why compliance often just "proves activity" rather than reducing real risk . Whether you're drowning in Jira tickets or trying to automate remediation, this episode provides a roadmap for modernizing your security postureGuest Socials - Brad's LinkedinPodcast Twitter - @CloudSecPod If you want to watch videos of this LIVE STREAMED episode and past episodes - Check out our other Cloud Security Social Channels:-Cloud Security Podcast- Youtube- Cloud Security Newsletter If you are interested in AI Security, you can check out our sister podcast - AI Security PodcastQuestions asked:(00:00) Introduction(02:50) Who is Brad Hibbert? (Brinqa)(04:55) The Evolution: From Scanning Servers to Cloud Complexity (06:50) What is Risk-Based Vulnerability Management? (08:50) Risk Owners vs. Remediation Owners: Who Fixes What? (12:00) How AI is Changing Vulnerability Management (15:20) Defining Exposure Management: Moving Beyond the Tools (18:30) The Challenge of "Data Inconsistency" Between Tools (22:30) Readiness Check: Are You Ready for Exposure Management? (25:10) Automated Remediation: Is "Zero Tickets" Possible? (28:40) Compliance vs. Risk: Why "Activity" isn't "Impact" (31:30) Maturity Milestones for Exposure Management (36:50) Fun Questions: Golf, Turkish Kebabs & Friendships
You have a "God-level" product. Your pricing is perfect. Your UI is beautiful. So why aren't customers buying? In this video, Ashish breaks down the brutal reality of why great SaaS products fail—and it has nothing to do with your features.Most founders make the mistake of trying to change a company's behavior. In SaaS, if your customer doesn't already have an existing workflow for the problem you're solving, you aren't just selling a tool—you're trying to change a culture. That is a losing battle for early-stage startups.What You'll Learn- Why "God-level" products still get rejected by the mid-market.- The massive difference between Consumer growth loops and Enterprise reality.
Is "developer-friendly" AI security actually possible? In this episode, Bryan Woolgar-O'Neil (CTO & Co-founder of Harmonic Security) joins Ashish to dismantle the traditional "block everything" approach to security.Bryan explains why 70% of Model Context Protocol (MCP) servers are running locally on developer laptops and why trying to block them is a losing battle . Instead, he advocates for a "coaching" approach, intervening in real-time to guide engineers rather than stopping their flow .We dive deep into the technical realities of MCP (Model Context Protocol), why it's becoming the standard for connecting AI to data, and the security risks of connecting it to production environments . Bryan also shares his prediction that Small Language Models (SLMs) will eventually outperform general giants like ChatGPT for specific business tasks .Guest Socials - Bryan's Linkedin Podcast Twitter - @CloudSecPod If you want to watch videos of this LIVE STREAMED episode and past episodes - Check out our other Cloud Security Social Channels:-Cloud Security Podcast- Youtube- Cloud Security Newsletter If you are interested in AI Security, you can check out our sister podcast - AI Security PodcastQuestions asked:(00:00) Introduction(01:55) Who is Bryan Woolgar-O'Neil?(03:00) Why AI Adoption Stops at Experimentation(05:15) The "Shadow AI" Blind Spot: Firewall Stats vs. Reality (08:00) Is AI Security Fundamentally Different? (Speed & Scale) (10:45) Can Security Ever Be "Developer Friendly"? (14:30) What is MCP (Model Context Protocol)? (17:20) Why 70% of MCP Usage is Local (and the Risks) (21:30) The "Coaching" Approach: Don't Just Block, Educate (25:40) Developer First: Permissive vs. Blocking Cultures (30:20) The Rise of the "Head of AI" Role (34:30) Use Cases: Workforce Productivity vs. Product Integration (41:00) An AI Security Maturity Model (Visibility -> Access -> Coaching) (46:00) Future Prediction: Agentic Flows & Urgent Tasks (49:30) Why Small Language Models (SLMs) Will Win (53:30) Fun Questions: Feature Films & Pork Dumplings
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
This Episode is brought to you by Urban Platter, to know more checkout: https://bit.ly/urban-platter-figuring-outGuest Suggestion Form: https://forms.gle/bnaeY3FpoFU9ZjA47Disclaimer: This video is intended solely for educational purposes and opinions shared by the guest are his personal views. We do not intent to defame or harm any person/ brand/ product/ country/ profession mentioned in the video. Our goal is to provide information to help audience make informed choices. The media used in this video are solely for informational purposes and belongs to their respective owners.Order 'Build, Don't Talk' (in English) here: https://amzn.eu/d/eCfijRuOrder 'Build Don't Talk' (in Hindi) here: https://amzn.eu/d/4wZISO0Follow Our Whatsapp Channel: https://www.whatsapp.com/channel/0029VaokF5x0bIdi3Qn9ef2JSubscribe To Our Other YouTube Channels:-https://www.youtube.com/@rajshamaniclipshttps://www.youtube.com/@RajShamani.Shorts(00:00) - Intro(03:16) - Why people hate successful people(09:55) - Why do people think rich people are evil?(13:45) - His relationship with his parents & insecurity(23:18) - Weight loss & how things changed after it(31:46) - His biggest fear(34:18) - God complex & his red flags(38:03) - Heartbreak(42:56) - Loneliness(47:21) - The biggest responsibility of a man(51:35) - Being on the same team since the beginning & trust issues(1:00:26) - His idea of therapy(1:01:54) - Toxic vs Dhurandhar 2(1:03:39) - Ekaki(1:08:49) - Facing rejection during Bollywood auditions(1:16:30) - The Elli AvrRam controversy(1:20:53) - Biggest insecurity & dream today(1:24:19) - BTS(1:25:35) - OutroIn today's episode, we have Ashish Chanchlani, director and actor, in a raw conversation about success, insecurity, and what it actually costs to grow in public.The conversation moves into loneliness, fear, trust issues, and why men are taught to suppress emotions. He reflects on responsibility, relationships, the one rule that matters in love, and why being too sweet can backfire. We also discuss Ekaki, his most invincible year, creative risks, Rajamouli's strategy, Elli AvrRam, and his biggest inferiority complex. This episode is honest, intense, and deeply human.Subscribe for more such conversations.Follow Ashish Chanchlani Here:Instagram: https://www.instagram.com/ashishchanchlaniAbout Raj ShamaniRaj Shamani is an Entrepreneur at heart that explains his expertise in Business Content Creation & Public Speaking. He has delivered 200+ speeches in 26+ countries. Besides that, Raj is also an Angel Investor interested in crazy minds who are creating a sensation in the Fintech, FMCG, & passion economy space.To Know More,Follow Raj Shamani On ⤵︎Instagram @RajShamani https://www.instagram.com/rajshamani/Twitter @RajShamani https://twitter.com/rajshamaniFacebook @ShamaniRaj https://www.facebook.com/shamanirajLinkedIn - Raj Shamani https://www.linkedin.com/in/rajshamani/About Figuring OutFiguring Out Podcast is a Candid Conversations University where Raj Shamani brings raw conversations with the Top 1% in India.
From growing up in small-town Shahabad to walking away from a stable job to chase freedom, from being called “cringe” online to becoming one of India's most talked about digital creators — Apoorva opens up about the chaos behind the confidence.She shares the heartbreaks, hate comments, and healing that shaped her, how she rebuilt herself after her lowest phases, and the moments that made her fearless — including that unforgettable table fall in Greece!In this heart-to-heart, between 2 different generations, Ashish and Apoorva explore the real story behind The Traitors, the pressures of social media fame, and the courage it takes to start over again and again.Raw, funny, and deeply human — this isn't just a podcast episode. It's a mirror into how today's generation is rewriting how they choose to define success, self-worth, and freedom. Chapters include:social media journey, creators India, online hate, creative burnout, mental health, The Traitors India, content creator economy, authenticity, self-expression, and reinvention.#AshishVidyarthi #TheRebelKid #ApoorvaMukhija #WithAshish #Podcast #CreatorJourney #SocialMedia #TheTraitors #Creators #AshishVidyarthiPodcast #Authenticity #realtalk
This week on Hafta, Newslaundry's Manisha Pande, Jayashree Arunachalam, and Anand Vardhan are joined by journalist Nikhil Inamdar and Sudipto Mondal, executive editor of The News Minute.Check out previous Hafta recommendations, references, songs and letters.Produced by Amit Pandey, with assistant production by Ashish ,Sound by Anil Kumar Hosted on Acast. See acast.com/privacy for more information.
A Song, A Step, A Second Chance... Meet the man behind timeless songs like Bawra Mann, Piyu Bole, and O Ri Chiraiya. From selling vacuum cleaners in Indore to winning National Awards and penning some of Bollywood's most memorable music, Swanand Kirkire's journey is one of courage, flow, and creativity.What happens when two multi-talented artists—Ashish Vidyarthi and Swanand Kirkire—reunite after decades? This deeply personal, music-filled conversation traces how risks, rejections, and relentless hope can turn ordinary moments into extraordinary turning points.From growing up in a musical Marathi household and auditioning at NSD, to writing the lyrics that shaped Bollywood, Swanand opens up about heartbreaks, accidents, and mentors who challenged him to say “yes” when it mattered most. Together, Ashish and Swanand share raw stories of acting, music, food, family expectations, and the freedom to fail—the greatest gift for any artist.Raw, heartwarming, and full of wit—this episode is a celebration of beginnings, setbacks, and the unpredictable music of life. Chapters include:Bollywood songwriting, NSD auditions, creative doubt, accidental successes, mentorship, Indian theatre, lyric-writing stories, food nostalgia, second acts, embracing failure, flow of life, positivity and the magic of “yes.”#AshishVidyarthi #SwanandKirkire #BollywoodMusic #Lyricist #Podcast #ActingJourney #WithAshish #MusicalStories #IndoreFood #NSD #CreativeJourney #HeartToHeartCome be a part of My YouTube Family ️️ / @ashishvidyarthiactorvlogs ️ / @ashishvidyarthipodcast ️ / @fiftypluszindagi ️ / @foodkhaanawithashishvidyarthi ️ / @kahaniyaanwithashishvidyarthi Press the bell icon. Be the first to get notified each time I upload a new video.Alshukran Bandhu,Alshukran Zindagi.
If you enjoy this episode, we're sure you will enjoy more content like this on The Occult Rejects. In fact, we have curated playlists on occult topics like grimoires, esoteric concepts and phenomena, occult history, analyzing true crime and cults with an occult lens, Para politics, and occultism in music. Whether you enjoy consuming your content visually or via audio, we've got you covered - and it will always be provided free of charge. So, if you enjoy what we do and want to support our work of providing accessible, free content on various platforms, please consider making a donation to the links provided below. Thank you and enjoy the episode!Links For The Occult Rejects and The Spiritual Gangsters https://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Cash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejects
If you enjoy this episode, we're sure you will enjoy more content like this on The Occult Rejects. In fact, we have curated playlists on occult topics like grimoires, esoteric concepts and phenomena, occult history, analyzing true crime and cults with an occult lens, Para politics, and occultism in music. Whether you enjoy consuming your content visually or via audio, we've got you covered - and it will always be provided free of charge. So, if you enjoy what we do and want to support our work of providing accessible, free content on various platforms, please consider making a donation to the links provided below. Thank you and enjoy the episode!Links For The Occult Rejects and The Spiritual Gangsters https://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Cash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejects
This week on Hafta, Newslaundry's Abhinandan Sekhri, Manisha Pande and Jayashree Arunachalam are joined by journalist and entrepreneur Govindraj Ethiraj. The discussion opens up with the recently concluded World Economic Forum held in Davos. Abhinandan sharply questions the performative nature of Indian participation at the forum, criticising chief ministers for announcing Memorandums of Understanding (MoUs) with Indian companies on foreign soil. “We are funding the circus,” Jayashree remarks bluntly, calling Davos a “clown show” driven by optics rather than outcomes.Govindraj also agrees that announcing MoUs, especially with Indian firms, is a misallocation of time and attention, given how the WEF offers leaders “an opportunity to gauge the temperature of what is happening in the world order right now”. The discussion also touches on the much-touted India-EU free trade agreement, which European Commission president Ursula von der Leyen described as the “mother of all deals”. Govindraj, however, tempers expectations, warning that free trade agreements are often narrow and slow-moving. “The first bottle of cheaper Scotch won't arrive tomorrow – it could take five years,” he quips.He further adds, “The red lines for India are clearly dairy and agricultural products… You can't do something which immediately jeopardises your farming lobby. So, if you take away agriculture and cheese, what's left now?”From Davos, the conversation shifts to press freedom in Jammu and Kashmir. Speaking on the recent summonses sent national media reporters by the J&K Police, Manisha remarks, “Over the last one year, at least 25 journalists have been summoned by the J&K Police… anything at all can just land you in a police station being questioned, because it's ‘public disorder', you're causing ‘public safety' disorder.”Drawing a contrast between reporters in New Delhi and Kashmir, Abhinandan says, “It's very difficult for someone in J&K to tough it out because there is no insulation. Delhi provides great insulation; that's why those headquartered in Delhi have to step up and protect their reporters who are not in Delhi.This and a lot more. Tune in!Timecodes00:00:00 - Introductions and announcements00:04:40 - Headlines 00:17:15 - WEF Davos / India- Eu trade deals 00: 55:59 - Govind' recommendations01:08:51 - Kashmir reporter's summoning 01:17:35 - Letters01:28:07 - RecommendationsCheck out previous Hafta recommendations, references, songs and letters.Produced by Amit Pandey, with assistant production by Ashish, Sound by Anil Kumar Hosted on Acast. See acast.com/privacy for more information.
Is the AI SOC a reality, or just vendor hype? In this episode, Antoinette Stevens (Principal Security Engineer at Ramp) joins Ashish to dissect the true state of AI in detection engineering.Antoinette shares her experience building detection program from scratch, explaining why she doesn't trust AI to close alerts due to hallucinations and faulty logic . We explore the "engineering-led" approach to detection, moving beyond simple hunting to building rigorous testing suites for detection-as-code .We discuss the shrinking entry-level job market for security roles , why software engineering skills are becoming non-negotiable , and the critical importance of treating AI as a "force multiplier, not your brain".Guest Socials - Antoinette's LinkedinPodcast Twitter - @CloudSecPod If you want to watch videos of this LIVE STREAMED episode and past episodes - Check out our other Cloud Security Social Channels:-Cloud Security Podcast- Youtube- Cloud Security Newsletter If you are interested in AI Security, you can check out our sister podcast - AI Security PodcastQuestions asked:(00:00) Introduction(02:25) Who is Antoinette Stevens?(04:10) What is an "Engineering-Led" Approach to Detection? (06:00) Moving from Hunting to Automated Testing Suites (09:30) Build vs. Buy: Is AI Making it Easier to Build Your Own Tools? (11:30) Using AI for Documentation & Playbook Updates (14:30) Why Software Engineers Still Need to Learn Detection Domain Knowledge (17:50) The Problem with AI SOC: Why ChatGPT Lies During Triage (23:30) Defining AI Concepts: Memory, Evals, and Inference (26:30) Multi-Agent Architectures: Using Specialized "Persona" Agents (28:40) Advice for Building a Detection Program in 2025 (Back to Basics) (33:00) Measuring Success: Noise Reduction vs. False Positive Rates (36:30) Building an Alerting Data Lake for Metrics (40:00) The Disappearing Entry-Level Security Job & Career Advice (44:20) Why Junior Roles are Becoming "Personality Hires" (48:20) Fun Questions: Wine Certification, Side Quests, and Georgian Food
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
In this episode, we sit down with Ashish Shanker, MD & CEO of Motilal Oswal Private Wealth, which now oversees over ₹1.9 Lakh Crore in assets under advisory. Ashish breaks down his strategy for 2026, revealing the one "non-obvious" sector poised to surprise the market, why silver might outperform gold, and how high-net-worth investors are hedging against global volatility.[Important note - This episode was recorded on December 5, 2025. Many market factors have changed since then. The content in this video is for educational and informational purposes only and does not constitute professional financial or investment advice. The views expressed by the guest are their own. Please consult with a certified financial advisor before making any investment decisions.]We dive deep into:* Why 2026 might see a fresh uptrend after 2025's consolidation.* The "capacity paradox" of managing wealth for ultra-high-net-worth families.* Actionable advice on US market diversification and pre-IPO investing rules.Timestamps:(00:00) - Episode Teaser & Introduction(02:24) - The Non-Obvious Sector to Watch in 2026(03:56) - Hedging Portfolios Against US Tariffs(07:20) - Is the Market Pricing in Too Much Perfection for 2026?(10:34) - NIFTY 50 vs. Mid & Small Caps for Long-Term Growth(11:46) - Silver: A Strategic Allocation or a Tactical Trade?(14:30) - The Gold-to-Silver Price Ratio: Is Gold Overvalued?(15:13) - Is It Time to Go 100% Aggressive on Mid-Caps?(18:21) - Impact of Rising Japanese Interest Rates on Indian Markets(22:22) - The Role of Domestic Investments in Market Resilience(24:14) - Protecting Portfolios from Rupee Depreciation(25:49) - Most Attractive Global Markets for Indian HNIs(27:35) - Investing Beyond the $250,000 LRS Limit(28:34) - Navigating the Pre-IPO and IPO Market(34:35) - The Relationship Manager (RM) Capacity Paradox(38:15) - Risk Appetite of Young Tech Founders vs. Traditional Promoters(39:47) - Is GIFT City Gaining Traction for Global Diversification?(41:09) - Physical Real Estate vs. REITs for Investment(41:57) - Essential Estate Planning Moves Before March 2026(43:21) - Ashish Shankar's Personal Investment Philosophy(44:42) - The Secret to Motilal Oswal's Success(48:05) - The Motilal Oswal Private Wealth Client Journey(51:35) - One Asset Class to Buy and Hold Until 2030(52:42) - Where to Learn More About Motilal Oswal Private WealthLinks:Motilal Oswal Private Wealth - https://www.motilaloswalpwm.com/Ashish Shanker on Linkedin - https://www.linkedin.com/in/ashishshanker23/Prashant Choubey - https://www.linkedin.com/in/choubeysahabSubscribe to VC10X newsletter - https://vc10x.beehiiv.comSubscribe on YouTube - https://youtube.com/@VC10X Subscribe on Apple Podcasts - https://podcasts.apple.com/us/podcast/vc10x-investing-venture-capital-asset-management-private/id1632806986Subscribe on Spotify - https://open.spotify.com/show/7F7KEhXNhTx1bKTBFgzv3k?si=WgQ4ozMiQJ-6nowj6wBgqQVC10X website - https://vc10x.comFor sponsorship queries, reach out to prashantchoubey3@gmail.com
In this episode of The Executive Room, host Kimberly Afonso (CEO & Founder, KA Consulting Group) sits down with Ashish Saxena, Chief Growth Officer at CoreStack, to explore how leaders can drive sustainable growth amid constant disruption.Ashish shares his highlights from 2025, including stepping outside his comfort zone, advising private equity firms on technology investments, publishing his new book The Growth Mandate: Leadership in an Exponential World, and stepping into his new role leading growth at CoreStack, an AI-powered cloud governance and security company.We discuss:How to operationalize a growth mindset through vision, strategy, execution, and customer centricityThe leadership shift required to restructure your business for AIHow CoreStack applies AI for productivity, product innovation, FinOps, CloudOps, and SecOpsWhy visibility matters and practical advice for leaders to build thought leadershipHow The Growth Mandate offers a manual for leaders with exercises and seven leadership levers.The questions every leader should ask about growth, technology, community, and legacyIf you're a CEO, founder, or growth leader navigating AI and transformation, this episode offers practical insights on how to align purpose with performance and build growth that lasts.
Ashish Prashar joins Anthony Davis to discuss how world leaders are responding to Trump's aggressive assault on the global order. The ‘No New War' President who has stirred conflict in Gaza, Iran, Yemen and Nigeria. The true reason behind his attacks on Venezuela, Greenland and how NATO can respond without sabotaging the alliance - only on The Weekend Show. Shopify: Sign up for a one-dollar-per-month trial period at: https://shopify.com/WEEKEND Independent media has never been more important. Please support this channel by subscribing here: https://www.youtube.com/channel/UCkbwLFZhawBqK2b9gW08z3g?sub_confirmation=1 Join this channel with a membership for exclusive early access and bonus content: https://www.youtube.com/channel/UCkbwLFZhawBqK2b9gW08z3g/join Buy Anthony's microphone: https://kellards.com/products/electro-voice-re20-broadcast-announcer-microphone-black-bundle-with-mic-shockmount-broadcast-arm Buy Anthony's black t'shirt: https://www.uniqlo.com/us/en/products/E455365-000/00?colorDisplayCode=09 Five Minute News is an Evergreen Podcast, covering politics, inequality, health and climate - delivering independent, unbiased and essential news for the US and across the world. Visit us online at http://www.fiveminute.news Follow us on Bluesky https://bsky.app/profile/fiveminutenews.bsky.social Follow us on Instagram http://instagram.com/fiveminnews Support us on Patreon http://www.patreon.com/fiveminutenews You can subscribe to Five Minute News with your preferred podcast app, ask your smart speaker, or enable Five Minute News as your Amazon Alexa Flash Briefing skill. CONTENT DISCLAIMER The views and opinions expressed on this channel are those of the guests and authors and do not necessarily reflect the official policy or position of Anthony Davis or Five Minute News LLC. Any content provided by our hosts, guests or authors are of their opinion and are not intended to malign any religion, ethnic group, club, organization, company, individual or anyone or anything, in line with the First Amendment right to free and protected speech. Learn more about your ad choices. Visit megaphone.fm/adchoices
Website: https://www.position2.com/podcast/Rajiv Parikh: https://www.linkedin.com/in/rajivparikh/Sandeep Parikh: https://www.instagram.com/sandeepparikh/Email us with any feedback for the show: sparkofages.podcast@position2.com
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
Every two years, Ligonier Ministries and Lifeway Research release The State of Theology—a massive survey that reveals what Americans (including evangelicals) actually believe about God, the Bible, Jesus, and culture. The 2025 report is out, and some of the numbers are… surprising. In this episode of Thinking Christian, Dr. James Spencer is joined by longtime friend and theologian Dr. Ashish Varmafor a wide-ranging conversation about what the data shows—and what it doesn’t show—about the theological landscape among evangelicals today. Rather than panicking over headline-grabbing statistics, James and Ashish analyze the deeper trends beneath the numbers. Together they explore: Why young evangelicals differ sharply from older generations on questions like the Bible’s literal truth and whether science conflicts with Scripture. Why nearly all evangelicals still say the Bible is their highest authority, even when their answers elsewhere seem to contradict that claim. How access to information, cultural context, and community shape belief—for better or worse. The surprising power of church attendance and affiliation in reinforcing core doctrines (and where that influence seems to break down). Why political theology may be quietly distorting how Christians answer moral questions—especially younger believers. Which troubling survey results actually matter—and which ones may simply reflect fuzzy categories or ambiguous wording. How churches should respond: not with panic or doctrinal hammering, but with thoughtful discipleship, richer community life, and deeper formation. James and Ashish also dive into the complexities of interpreting theological surveys at all—how beliefs are shaped by cultural habitus, how people understand (or misunderstand) terms like myth, literal, or love, and why surveys often reveal more about our formation than our formal theology. If you’re curious about what evangelicals really believe—and what the church can do about it—this episode offers a hopeful, nuanced, and deeply thoughtful guide through the data. Subscribe to our YouTube channel
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
In this episode, we take a deep dive into the global climate-tech ecosystem, with a focus on how innovation can be translated into deployment, and what needs to be done to scale renewable integration. We are joined by Ashish Khanna, Director General, International Solar Alliance, to explore where do we lack when it comes to accelerating climate-tech innovation. He says it is important to see the glass half full and India has an immense potential, it can become a hotbed for innovation. Building on the momentum created by ENTICE, this episode explores how ideas become deployable solutions - through financing, policy support, and real-world testing. Tune in!
Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
In this episode of The Digital Executive, Brian Thomas interviews Ashish Aggarwal, Co-Founder of AppBroda—a no-code ad network empowering mobile app and game developers to scale revenue without writing a single line of code. Drawing on his experience at Google working with thousands of developers, Ashish explains the industry's biggest friction point: developers don't want additional SDKs or code that slow apps, risk crashes, or violate privacy rules.Ashish shares how AppBroda solves that challenge with automated, data-driven monetization tools now used by over 2,000 studios, contributing to more than $2B in annual recurring revenue. He breaks down what separates consistently successful studios—data-driven systems, adaptability, and access to capital—and how privacy shifts and platform policies have reshaped mobile ad economics.Looking ahead, Ashish predicts a new era where AI enables anyone to become an app or game creator. He explains how no-code platforms like AppBroda will power this next wave of digital entrepreneurs by simplifying monetization for non-technical builders. This conversation is a must-listen for developers, creators, and anyone following the future of mobile apps.If you liked what you heard today, please leave us a review - Apple or Spotify. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this powerful episode of Fuel for the Harvest, Nathan shares an extraordinary collection of firsthand recordings from Ashish — a faithful Forge Ambassador serving in Bangladesh, one of the most densely populated and spiritually challenging Muslim nations in the world.What began as a single laborers training just six months ago has now erupted into a rapidly multiplying gospel movement. Ashish and his team have already trained over 1,000 laborers, launched 100+ cell groups, distributed hundreds of Bibles, and seen countless people — including those from Muslim backgrounds — respond to Jesus.
Are driving assistance systems making the roads safer? Ashish Agarwal, professor in the IROM Department of Management in the McCombs School of Business at The University of Texas at Austin, gets behind the wheel to find out. Ashish Agarwal is a professor of information, risk, and operations management at The University of Texas at Austin's […]
In this powerful talk, Ashish Vidyarthi dives deep into the feeling of guilt that often holds us back from making a fresh start. Whether you're thinking about changing careers, moving cities, or simply choosing a different path, this is a reminder that you don't owe anyone an explanation for your choices .Ashish shares his own vulnerable story of reinventing himself—from being a famous on-screen villain to becoming a speaker, traveler, and storyteller—and the fear he faced along the way.In this video, you'll discover:Why starting over is a sign of growth, not failure .How to release what no longer serves you, without apology or shame .That you have permission to build a life that fits who you are today .The quiet power of gently closing one door and opening another.As Ashish says, "You are allowed to begin again without apology, without shame, without guilt" . It's time to hug yourself for the journey and embrace the possibility of a new chapter .Say it with us: I AM POSSIBLE!#AshishVidyarthi #StartingOver #Motivation #LetGoOfGuilt #PersonalGrowth #Inspiration #NewBeginnings #SelfHelp #IAmPossible
Do you ever wake up feeling overwhelmed, misunderstood, or that life is just too heavy to carry?In this heartfelt and moving podcast, Ashish Vidyarthi shares a powerful message for everyone navigating a difficult chapter.Life isn't always about winning; sometimes, it's about acknowledging that you're not okay and finding the strength to take just one more step.Ashish talks about his own struggles as a self-employed actor facing rejection and uncertainty, and how these moments pushed him to discover new paths as a vlogger, speaker, and innovator.In this episode, you will discover:Why it's crucial to be "okay with not being okay".How to choose your response, even when you can't control what's happening around you.The power of "tiny wins" to build momentum and shift your mindset.How to reframe the question from "Why is this happening to me?" to "What is life pushing me towards?".The strength in reaching out for help and sharing your truth.This isn't just a lecture; it's a gentle reminder that you are not stuck, you are not alone, and your story is still being written by you. Remember, I Am Possible.If this message resonates with you, please Like, Share, and Subscribe for more conversations that uplift and inspire.What's one "tiny win" you can gift yourself today?#AshishVidyarthi #Motivation #Inspiration #WhenLifeFeelsHeavy #MentalWellness #SelfHelp #PositiveThinking #DealingWithFailure #OvercomingObstacles #IAmPossible
Have you ever been made to feel small, unworthy, or invisible? In this powerful episode, Ashish Vidyarthi shares his personal experiences and heartfelt advice on how to deal with being looked down upon.In a world where it's easy to feel dismissed, Ashish explains that no one can make you feel small unless you give them that right. This episode is a guide to rewriting the negative stories you tell yourself and reclaiming your power.In this video, you will learn:Why someone looking down on you is more about their own insecurities than it is about you.The power of changing your inner narrative from "I'm not good enough" to "I am who I choose to become".Practical steps to rise above negativity without anger or revenge.Why your growth is the most powerful response to those who doubt you.The importance of becoming your own biggest cheerleader and celebrating your journey.Join Ashish as he guides you to stop seeking validation from others and start building unshakable self-worth. It's time to walk tall, keep your spirit high, and remember: I Am Possible.#AshishVidyarthi #Motivation #SelfWorth #Inspiration #PersonalGrowth
What if working less could help us live more — with greater energy, purpose, and joy?In this eye-opening conversation, Ashish Kothari sits down with Karen Lowe, South Africa's lead advocate for the 4-Day Workweek movement and founder of 4 Day Week South Africa, to explore how shorter work weeks are transforming productivity, culture, and well-being across the globe.Karen shares how a passion project in Cape Town became the world's fourth major pilot of the 4-Day Workweek — and the results are nothing short of revolutionary: higher revenue, lower burnout, better sleep, deeper engagement, and teams that flourish together.This episode challenges the modern obsession with “more” and makes a powerful case for the 4-day week as both a science-backed productivity strategy and a human sustainability movement.
Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
Grow your management tools for opioid withdrawal in the hospital. Investigate how to decide between methadone and buprenorphine, additional medications to manage symptoms and how and when to use short-acting opioids for management of withdrawal. We're joined by Ashish Thakrar, MD at the University of Pennsylvania. Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Show Segments Intro, disclaimer, guest bio Guest one-liner Case from Kashlak; Definitions Symptoms of opioid withdrawal Medications for the management of opioid withdrawal Buprenorphine precipitated withdrawal Starting Buprenorphine: Experiences and Strategies Titrating Methadone: Dosage and Adjuncts Adjunctive short-acting opioids Emerging Trends in Drug Supply: Xylazine and Medetomidine Outro Credits Producer, Show Notes: Zina Huxley-Reicher Infographics: Zina Huxley-Reicher MD and Zoya Surani Hosts: Carolyn Chan, MD MHS, Zina Huxley-Reicher MD, Shawn Cohen, MD Reviewer: Payel Jhoom Roy, MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Ashish Thakrar, MD MHSP
What if the most painful moments in life could become the greatest catalysts for growth?In this deeply moving episode of The Flourishing Edge, Ashish Kothari sits down with Ian Ziskin, President of EXec EXcel Group LLC, author, and leadership thought leader, to explore the powerful connection between loss, learning, and leadership.Ian shares the personal story that shaped his life from age 13 — losing his father to multiple sclerosis — and how that early experience of grief forged his lifelong commitment to intentional living, compassion, and resilience. Together, Ashish and Ian unpack what it truly means to flourish through adversity, why intentionality (not time) heals wounds, and how leaders can create workplaces where people feel trusted, valued, and alive.This episode is a masterclass in transforming suffering into strength — and leading with both heart and purpose.
Welcome Online Family! Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones. ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch
Every five years, resuscitation guidelines get a refresh. This year, a few have changed, many have stayed the same, and some are creating major controversy.In this episode, Dr. Ashish Panchal, Chair of the AHA Emergency Cardiovascular Care Committee, helps us unpack what's new, what might surprise you, and the science behind each decision. You'll learn why there's serious debate around epinephrine dosing, what changes matter most for the bedside, and how these updates will change the way you and your team respond to the next code!Topics discussed in this episode:The history and development of the AHA Resuscitation GuidelinesKey improvements: algorithms, clear language, and unified careBig, fundamental changes in the guidelinesHow choking management guidelines have changedThe recommended approach for synchronized cardioversionNew guidelines for post-resuscitation careWhy there's controversy around mechanical CPR and DSDIV vs. IO access: best practice and key takeawaysThe controversy around epinephrine dosingWhat these changes mean for nurses and code teamsListen to E140 with Dr. Ashish Panchal:https://healthpodcastnetwork.com/episodes/rapid-response-rn/140-resuscitation-then-and-now-how-evidence-shapes-every-beat-with-guest-dr-ashish-panchal-md-phd/Mentioned in this episode:AND If you are planning to sit for your CCRN and would like to take the Critical Care Academy CCRN prep course you can visit https://www.ccrnacademy.com and use coupon code RAPID10 to get 10% off the cost of the course!CONNECT
Technology promised us progress, and it delivered. But it also left us disconnected, distracted, and disheartened at the same time. With AI advancing faster than human adaptation or regulation, will it erode our humanity, or can it become the very tool that helps us flourish?In this episode of the Happiness Squad Podcast, Ashish Kothari sits down with Tamara Lechner to explore how AI can bridge the gap between what we know and what we practice in the pursuit of human flourishing.Tamara Lechner is a happiness expert, author, and global speaker. As Chair of the AI & Human Flourishing Working Group at Harvard, she helps leaders and organizations apply the science of flourishing to create meaningful, human-centered futures.In the conversation, Ashish and Tamara unpack how AI can either harm or uplift us, and what it will take for leaders, organizations, and individuals to put humans at the heart of this powerful technology.Things you will learn in this episode:• Why AI is both friend and foe depending on how we use it.• The three ethical AI pillars: productivity, protection from harm, and fairness.• The overlooked dimensions of flourishing AI must support• Why organizations—not just individuals—must own responsibility for burnout and culture.• How to shift from audience to activist in shaping the future of technologyJoin us in building a future where technology enhances humanity rather than diminishes it. Tune in now to hear how we can harness AI to truly help humans flourish.✅Resources:• How to make flourishing your competitive edge | Ashish Kothari | TEDxGreenhouse Road: https://www.youtube.com/watch?v=eRV-2C-fkNg • AI for Human Flourishing: https://www.aiforhumanflourishing.com/• The Human Flourishing Program: https://hfh.fas.harvard.edu/ai-human-flourishing • Reframing employee health: Moving beyond burnout to holistic health by McKinsey Health Institute: https://www.mckinsey.com/mhi/our-insights/reframing-employee-health-moving-beyond-burnout-to-holistic-health• Conscious Capitalism Movement: https://www.consciouscapitalism.org/ • IEEE 7010: A New Standard for Assessing the Well-being Implications of Artificial Intelligence: https://arxiv.org/pdf/2005.06620 ✅Books:• The Happiness Reset: What to do When Nothing Makes You Happy by Tamara Lechner: https://a.co/d/gZY7eXu • Hardwired for Happiness: 9 Proven Practices to Overcome Stress and Live Your Best Life by Ashish Kothari: https://a.co/d/9LWxYmV
Grow your management tools for opioid withdrawal in the hospital. Investigate how to decide between methadone and buprenorphine, additional medications to manage symptoms and how and when to use short-acting opioids for management of withdrawal. We're joined by Ashish Thakrar, MD at the University of Pennsylvania. Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Show Segments Intro, disclaimer, guest bio Guest one-liner Case from Kashlak; Definitions Symptoms of opioid withdrawal Medications for the management of opioid withdrawal Buprenorphine precipitated withdrawal Starting Buprenorphine: Experiences and Strategies Titrating Methadone: Dosage and Adjuncts Adjunctive short-acting opioids Emerging Trends in Drug Supply: Xylazine and Medetomidine Outro Credits Producer, Show Notes: Zina Huxley-Reicher Infographics: Zina Huxley-Reicher MD and Zoya Surani Hosts: Carolyn Chan, MD MHS, Zina Huxley-Reicher MD, Shawn Cohen, MD Reviewer: Payel Jhoom Roy, MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Ashish Thakrar, MD MHSP Sponsor: Mint Mobile Shop plans at MINTMOBILE.com/CURB Sponsor: Freed Use code: CURB50 to get $50 off your first month when you subscribe! Sponsor: FIGS We've teamed up with FIGS, and now Curbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX.
© 2020-2026 Ivy Podcast Discovery LLC
